Alnylam Pharmaceuticals shares are up about 3% in Tuesday trading after a new Street note highlighted the stock with an updated price target of $505, adding incremental support to a rally that has already pushed ALNY into the mid-$300s. The target update is acting as the clearest same-day catalyst for the move, as traders react to a higher implied valuation and the prospect of continued earnings and revenue momentum.

For large-cap biopharma names, target changes can have an outsized impact when they reinforce a view that a company’s core franchise can sustain multi-year growth. With ALNY already trading near $343, the $505 target signals meaningful upside in analysts’ modeled scenarios, which can prompt short-covering, incremental institutional buying, and momentum flows—especially when broader healthcare tape is supportive.

Investors will focus on whether additional firms echo the more bullish target reset, and whether management’s next update reinforces confidence in near-term execution. Key swing factors include commercial performance of the TTR franchise, pipeline milestones, and any fresh regulatory or clinical updates that could expand addressable markets or shift competitive expectations.